Metaraminol
Metaraminol (metaraminol) is a small molecule pharmaceutical. Metaraminol was first approved as Metaraminol bitartrate on 1982-01-01. It is used to treat hypotension and shock in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Metaraminol (discontinued: Aramine, Metaraminol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metaraminol bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARAMINE | Merck & Co | N-009509 DISCN | 1987-12-22 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypotension | EFO_0005251 | D007022 | I95 |
| shock | — | D012769 | R57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0380 | Injection, metaraminol bitartrate, per 10 mg |
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstetric labor complications | D007744 | — | — | — | — | — | 2 | — | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | 1 | — | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | — | — | 1 | — | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypotension | D007022 | EFO_0005251 | I95 | — | 1 | 1 | — | 1 | 3 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 1 | — | 1 | 2 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metaraminol |
| INN | metaraminol |
| Description | Metaraminol is a member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension. It has a role as an alpha-adrenergic agonist, a sympathomimetic agent and a vasoconstrictor agent. |
| Classification | Small molecule |
| Drug class | Norepinephrine releasing agent; Adrenergic receptor agonist; Sympathomimetic; Antihypotensive |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](N)[C@H](O)c1cccc(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 54-49-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201319 |
| ChEBI ID | 6794 |
| PubChem CID | 5906 |
| DrugBank | DB00610 |
| UNII ID | 818U2PZ2EH (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,419 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
185 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use